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Abstract
Background and purpose: We created a scoring system incorporating dosimetric and clinical factors to assess the
risk of severe, acute skin reactions in patients undergoing intensity-modulated radiation therapy (IMRT) to treat
head and neck cancer (HNC).
Materials and methods: A total of 101 consecutive patients who received definitive IMRT or volumetric modulated
arc therapy (VMAT) with a prescription dose of 70 Gy to treat HNC between 2013 and 2017 in our hospital were enrolled.
Skin V5Gy, V10Gy, V20Gy, V30Gy, V40Gy, V50Gy, and V60Gy values delivered 5 mm within the body contour were
compared between patients with Grades 1–2 and Grade 3 dermatitis. A scoring system was created based
on logistic regression analysis (LRA) that identified the most significant dosimetric and clinical factors.
Results: The V60Gy was significantly associated with radiation dermatitis grade in both LRA and recursive partitioning
analysis (RPA). A scoring system incorporating the V60Gy, concurrent chemotherapy status, age, and body mass index
was used to divide all patients into three subgroups (0–1, 2–3, and 4–6 points) in the RPA. The incidence of Grade 3
dermatitis significantly differed among the subgroups (0, 20.5, and 58.6%, respectively, P < 0.01).
Conclusions: A risk analysis model incorporating dose-volume parameters successfully predicted acute skin reactions
and will aid in the appropriate management of radiation dermatitis.
Keywords: Head-and- neck cancer, IMRT, VMAT, Skin dose
Highlights
A scoring system predicting radiation dermatitis.
Introduction
Radiotherapy is a principal treatment for head and neck
cancer (HNC). Definitive radiotherapy in patients with
advanced HNC can preserve laryngopharyngeal functions
such as speaking, swallowing, and breathing. Radiotherapy
for HNCs must minimise exposure to a large number of
organs-at-risk (OARs). Intensity-modulated radiotherapy
(IMRT) reduces complications and escalates dose delivery
[1]. The radiation dose necessary to achieve local tumour
control is limited by doses to normal tissues within the
irradiation field [2, 3]. Radiation dermatitis is one of the
most common adverse events associated with head and
neck (HN) radiotherapy, and is radiation dose-dependent
[4]. During two- or three-dimensional conformal radio-
therapy (2D/3D-CRT), dose distribution to the skin is
homogeneous and can be easily estimated, but the radi-
ation dose delivered by IMRT is inhomogeneous and diffi-
cult to calculate. The significance of dose-volume factors
when performing radiotherapy is well recognised, and it is
preferable to minimise the skin dose, but no clear indica-
tion of the severity of acute skin reactions is available.
Radiation dermatitis has a profound impact not only on
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quality of life (QOL) but also on treatment outcomes; ra-
diation schedules may be interrupted [5–7]. Thus, predic-
tion of radiation dermatitis risk is essential for appropriate
management. A previous report suggested several predic-
tors of acute toxicities [8]; our current study includes both
dose-volume parameters and other clinical factors.
Here, we evaluated the relationship between skin dose
distributions and the incidence of severe, acute radiation
dermatitis in HNC patients treated with IMRT and volu-
metrically modulated arc therapy (VMAT). We devel-
oped a scoring system combining dose parameters with
clinical factors that usefully predicted acute skin reac-




We retrospectively identified 101 consecutive patients
with HNC, all of whom underwent definitive radiotherapy
of 70 Gy between 2013 and 2017 in our hospital. Patient
characteristics are shown in Table 1. Classification by
tumour histology revealed 99 squamous cell carcinomas, 1
adenocarcinoma, and 1 myoepithelial cancer. Two patients
were of stage I, 12 were of stage II, 18 were of stage III, and
69 were of stage IV; staging was done using the malignant
tumour criteria of the Union for International Cancer Con-
trol (7th edition) [9]. IMRT using a 4 MV photon beam
was used to treat 46 patients from 2013 to 2014, and
VMAT employing a 6 MV photon beam was used to treat
55 patients from 2014 to 2017. The median overall treat-
ment time was 50 days (range, 46–62 days). Written in-
formed consent was obtained from all patients, and the
study was approved by our local ethics committee.
IMRT and VMAT
All patients were immobilised in the supine position with
fixation mask and scanned over the neck and upper
thorax using the LightSpeed RT Computed Tomography
(CT) platform (2.5mm thick slices; GE Healthcare, Madi-
son, WI, USA). The critical structures and target volumes
were delineated by radiation oncologists and medical
physicists on axial slices. In line with ICRU Reports 50
and 62 [10, 11], the gross tumour volume (GTV) was de-
fined as the gross extent of tumour evident in CT images,
including both the primary tumour and gross regional
LNs. The clinical target volume (CTV) was defined as the
GTV plus a margin allowing for potential microscopic
tumour extension and encompassing the adjacent regional
LNs. The planning target volume (PTV) was the CTV
plus a 5mm wide margin to allow for uncertainties in ra-
diation delivery, the internal margin, and the set-up mar-
gin. The PTV70Gy volume included the primary tumour
and LN metastases, the PTV63Gy included the high-risk
LNs, and the PTV56Gy included the low-risk LNs. All
PTVs were clipped from the body contours by 3mm to
reduce the skin doses [12]. The principal OARs were the
spinal cord, brainstem, both parotid glands, and the oral
cavity. Critical organs (the brainstem and the spinal cord)
were assigned 5mm margins when generating planning
risk volumes. The nominal energies of the flattened pho-
ton beams of Clinac 6EX and Clinac iX (Varian Medical
Systems, Washington DC, USA) were 4 and 6 MV, respect-
ively. Dose calculations were performed using Acuros XB
software (ver. 13.7.14; Varian). The simultaneous integrated
boost technique was used to deliver 70, 63, and 56Gy in 35
fractions to the PTV70Gy, PTV63Gy, and PTV56Gy,
Table 1 Patient characteristics















Squamous cell carcinoma 99
Other 2
TNM stage N0 N1 N2 N3
T0–1 2 2 8 3
T2 9 3 23 3
T3 10 3 6 1









Abbreviations: IMRT intensity modulated radiotherapy, VMAT volumetric
modulated arc therapy
Neoadjuvant therapy: TPF (Docetaxel, Cisplatin, 5-Fluorouracil), TPE (Docetaxel,
Cisplatin, Cetuximab), FP (Cisplatin, 5-Fluorouracil), CDDP (Cisplatin), and
CBDCA (Carboplatin)
Adjuvant therapy: CDDP (Cisplatin), CBDCA (Carboplatin), and Cet (Cetuximab)
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respectively. The dose constraints of targets, and the OARs
used to optimise the IMRT and VMAT plans, met our in-
stitutional criteria (Table 2).
Skin evaluation
Both board certificated radiation oncologists and otolaryn-
gologists scored all incidents of acute radiation dermatitis
weekly during treatment and 1month after treatment using
the Common Terminology Criteria for Adverse Events
(CTCAE) ver. 4.0 [13]. The highest grade of toxicity served
as the reference value. The CTCAE for dermatitis defined
Grade 1 as faint erythema or dry desquamation; Grade 2 as
moderate to brisk erythema, patchy moist desquamation
(mostly confined to skin folds and creases), and moderate
edema; Grade 3 as moist desquamation in areas other than
skin folds and creases, and bleeding induced by minor
trauma or abrasion; and Grade 4 as life-threatening skin ne-
crosis or ulceration of the full-thickness dermis, spontan-
eous bleeding, and a need for skin grafts.
Dose-volume histogram analyses
An irradiation boundary of 5 mm inside the body con-
tour was automatically generated at a threshold of − 350
HU to evaluate skin structure using the definition of the
Radiation Therapy Oncology Group. Then dose-volume
histograms (DVHs) were calculated for the skin, which
served as a surrogate for the epidermis and dermis.
Statistical analyses
Statistical analyses were performed using EZR ver. 1.31
software (Saitama Medical Center, Jichi Medical University,
Saitama, Japan), which is a graphical user interface for R
(the R Foundation for Statistical Computing, Vienna,
Austria) [14]. The relationship between DVH parame-
ters and the acute effects on normal tissue were com-
pared using the Mann–Whitney U-test. The DVHs
yielded the absolute volumes of V5Gy, V10Gy, V20Gy,
V30Gy, V40Gy, V50Gy, and V60Gy. Vd Gy is the absolute
volume of skin that received more than the threshold
dose of d Gy. To evaluate the acute effects, patients
were subdivided by their CTCAE scores. The effects of
chemotherapy, treatment technique, sex, age, and body
mass index (BMI) were also recorded. The optimal
cut-off used to divide patients into two subgroups based
on the radiation dermatitis grade was defined using recur-
sive partitioning analysis (RPA). For dose-volume parame-
ters, threshold cut-offs were used to divide the population.
We also evaluated chemotherapy status, treatment tech-
nique, sex, age, and BMI via logistic regression analysis
(LRA) within multivariate technique. We used the median
age and lean BMI (< 18.5 kg/m2) to divide the population.
Patients were scored by reference to the V60Gy, concurrent
chemotherapy status, age, and BMI, all of which were sig-
nificant in LRA. Radiation dermatitis scores were also re-
corded. After dividing the groups via RPA, the rates of
Grade 3 dermatitis were compared using the Fisher’s exact
test. P values less than 0.05 were considered statistically
significant.
Results
Average DVHs were drawn for each patient and com-
pared to the acute skin dermatitis grade, which was our
clinical endpoint (Fig. 1a). Grade 1 dermatitis was ob-
served in 22 patients, Grade 2 was observed in 53, and
Grade 3 was observed in 26; no patient had Grade 4 or
5 disease. The average skin V20Gy and V60Gy values were
354.4 (range, 50.3–546.0), and 39.0 (range, 2.9–88.7
cm3). The means, standard deviations, and P-values for
all parameters of each grade are shown in Table 3.
Association between skin DVHs and acute dermatitis
The volumes of DVHs at each dose were related to the
incidence of Grade 3 dermatitis. The Mann–Whitney
U-test indicated a significant difference between Grade
1–2 and 3 patients. Comparison of the DVHs showed
that patients who developed worse skin reactions received
higher radiation skin dose, and that the skin dose was asso-
ciated with a greater risk of acute dermatitis. Although the
DVHs tended to differ at low doses of 10–20Gy (Fig. 1a),
the percentage differences were greater in the high-dose
area (60Gy) as revealed by the bar graph (Fig. 1b). The op-
timal cut-offs used to divide the patient population into
two subgroups based on radiation dermatitis grade are
shown in Table 4. The RPA and LRA showed that all dose
parameters were significant, particularly the V60Gy. The
probability of developing dermatitis in each grade by
Table 2 Planning constraints
Structure Index Objectives Acceptable
PTV70Gy D50% (%) 100% 98–103%
PTV70Gy D98% (%) > 93% > 90%
PTV70Gy D2% (%) < 105% < 115%
PTV63Gy D90% (Gy) 100% (63 Gy) > 97% (61.11Gy)
PTV63Gy D50% (Gy) < 105% (66.15 Gy) < 108% (68.04Gy)
PTV56Gy D90% (Gy) 100% (56 Gy) > 97% (54.32Gy)
PTV56Gy D50% (Gy) < 105% (58.8 Gy) < 108% (60.48Gy)
CTV70Gy D95% (%) > 100% > 98%
CTV63Gy D95% (Gy) > 100% (63 Gy) > 98% (61.74Gy)
CTV56Gy D95% (Gy) > 100% (56 Gy) > 98% (54.88Gy)
GTV D95% (%) > 100% > 98%
Spinal cord Max 45 Gy 50 Gy
Brain stem Max 54 Gy 60 Gy
Contralateral
parotid grand
V30Gy < 50% < 50%
Oral cavity Mean 30 Gy < 40 Gy
Abbreviations: DXX% dose to xx% of the organ; V30Gy volume receiving 30 Gy
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chemotherapy status, treatment technique, sex, age, and
BMI are shown in Table 5.
Scoring system for, and risk classification of radiation
dermatitis
All of the V60Gy, concurrent chemotherapy, age, and BMI
were significant in LRA. The estimated values of V60Gy,
BMI, age, and platinum and cetuximab chemotherapy
were 1.8311, 0.9547, 0.8699, 1.1227, and 2.2713, respect-
ively (Table 6). LRA showed that a V60Gy > 40.3 cm
3 scored
2 points, BMI < 18.5 kg/m2 scored 1 point, age ≥ 67 years
scored 1 point, platinum therapy scored 1 point, and
cetuximab therapy scored 2 points (Table 7). Using this
scoring system, patients were divided into three subgroups
(0–1 points, 2–3 points, and 4–6 points) in the RPA; the
incidences of Grade 3 dermatitis of low, intermediate, and
high risk group were 0, 20.5, and 58.6%, while those of
Grade 1 dermatitis were 42.8, 20.5, and 3.4%, respectively
(P < 0.01) (Table 6, Fig. 2). Representative images of pa-
tients with each grade are shown in Fig. 3.
Discussion
We evaluated the relationship between skin dose-volume
distributions and the incidence of severe, acute radiation
A
B
Fig. 1 a DVHs of patients with different dermatitis grades. b Bar graph of each dermatitis grade
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dermatitis in HNC patients treated with IMRT and VMAT.
We constructed a risk analysis model combining dose pa-
rameters with concurrent chemotherapy, age, and BMI.
The model usefully predicted acute skin reactions, facilitat-
ing the appropriate management of radiation dermatitis.
Acute dermatitis is the most common side effect of
HNC radiotherapy, and usually develops within 90 days
of exposure [15]. The skin of the anterior neck is the most
sensitive region of the body [16]. During radiotherapy,
ionisation of cellular water and generation of short-lived
free radicals trigger irreversible double-stranded breaks in
nuclear and mitochondrial DNA, as well as inflammation
[17–19]. Repeated exposure to low-dose ionizing radi-
ation prevents DNA and tissue repair. Accumulation of
radiation-induced changes in the dermal vasculature,
appendageal structures, and epidermal stem cells re-
sults in dermatitis progression through characteristic
stages that increase in severity. Radiation dermatitis is a
dose-dependent toxic effect. The total dose, dose per
fraction, and dose volume to surfaces exposed to radiation
affect radiation dermatitis risk. In the era of low-energy
techniques, skin changes depend on the radiation dose
(erythema after doses ≥2 Gy; dry desquamation after doses
of 12–20Gy, moist desquamation at doses > 20Gy, and
necrosis at doses ≥35 Gy). In terms of necrosis/ulceration
endpoints, the skin TD5/5 (the 5% probability of a
complication within 5 years of treatment) was 55 Gy
for a 100 cm2 field. The TD3/5 was 57 Gy for a 30
cm2 field and 69 Gy for a 10 cm2 field [20]. These
data revealed dose dependency of late skin reaction,
but they cannot be extrapolated to acute dermatitis.
It was needed to build the new indication of acute
dermatitis with dose volume analysis. In our study
V60Gy over 38cm
3 related to 43.4% of Grade 3 derma-
titis, and it could be a new indication to predict the
severity of radiation dermatitis induced by head and
neck IMRT/VMAT.
IMRT delivers radiation to the planned treatment vol-
ume while minimizing the dose to normal tissues out-
side the target, thus reducing skin reactions. Using
breast IMRT, a multicenter randomised trial showed that
fewer patients in the IMRT than the conventional radio-
therapy group experienced moist desquamation (31% vs.
48%) [21]. In HNC patients receiving IMRT, skin dose
accumulation markedly increased (reflecting the intrinsic
dose distribution profile) if no correction was applied in
terms of inverse planning optimisation after initial clin-
ical implementation [12]. When a thermoplastic mask
was used for immobilisation, the skin doses were higher
than those delivered without a mask because of a bolus
effect. By contouring the skin as an OAR during opti-
misation, the volumes of neck skin receiving > 45 Gy
and > 55 Gy fell to 58 and 17% of the initial values, re-
spectively. Penoncello et al. [22] reported that VMAT is
associated with fewer skin reactions than IMRT and is
better at reducing skin doses. In addition, integrated
boost regimens trigger higher skin doses, particularly to
the shoulders, compared to traditional boost regimens.
Price et al. found that a 4 mm PTV-to-skin distance
minimised the odds ratio for developing superficial “hot
spots” to < 1.1 when high-conformal rotational tech-
niques such as VMAT were applied [23]. It has been
suggested that the PTVs should be cropped 3mm below
the contoured body surface to prevent optimisation is-
sues in build-up regions, except when the skin is part of
the CTV (ICRU Report 83; [24]). Treatment protocol
1015 of the Japan Clinical Oncology Group, derived
Table 3 Comparisons of skin dose parameters among patients
with Grades 1–3 dermatitis
Skin (mean ± SD) Grade 1 Grade 2 Grade 3 P-value
V5 Gy (cm
3) 566 ± 224 693 ± 136 745 ± 85 < 0.01
V10 Gy (cm
3) 438 ± 197 568 ± 119 620 ± 81 < 0.01
V20 Gy (cm
3) 262 ± 128 365 ± 92 410 ± 73 < 0.01
V30 Gy (cm
3) 152 ± 75 216 ± 68 247 ± 48 < 0.01
V40 Gy (cm
3) 96 ± 45 133 ± 47 149 ± 28 < 0.01
V50 Gy (cm
3) 59 ± 30 83 ± 33 95 ± 24 < 0.01
V60 Gy (cm
3) 25 ± 17 40 ± 22 49 ± 16 < 0.01
Abbreviations: SD standard deviation, VdGy volume of the skin that received
more than the threshold dose of d Gy
P-value: derived by Mann–Whitney U-test comparisons between Grades 1–2
and Grade 3 patients
Table 4 Optimal cut-off values for and crude rates of Grade 3 radiation dermatitis
Cut-off value Grade 3 radiation dermatitis < Cut-off > Cut-off P-value
V5Gy (cm
3) 690 5/40 (12.5%) 21/61 (34.4%) 0.019
V10Gy (cm
3) 565 5/40 (12.5%) 21/61 (34.4%) 0.019
V20Gy (cm
3) 400 9/66 (13.6%) 17/35 (48.6%) < 0.01
V30Gy (cm
3) 190 2/38 (5.3%) 24/63 (38.1%) < 0.01
V40Gy (cm
3) 115 2/34 (5.9%) 24/67 (35.8%) < 0.01
V50Gy (cm
3) 85 8/54 (14.8%) 18/47 (38.3%) 0.011
V60Gy (cm
3) 38 6/55 (10.9%) 20/46 (43.4%) < 0.01 a
Abbreviations: VxxGy volume of the skin that received xx Gy
aV60Gy was the most significant dose parameter in both LRA and RPA
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Table 5 Effects of non-dose parameters on dermatitis grade
Grade 1 (n = 22) Grade 2 (n = 53) Grade 3 (n = 26) Total
Neoadjuvant chemotherapy
(−) 17 (28.3%) 34 (56.7%) 9 (15.0%) 60
(+) 5 (12.2%) 19 (46.3%) 17 (41.5%) 41
Concurrent chemotherapy
Radiotherapy alone 6 (26.1%) 15 (65.2%) 2 (8.7%) 23
Platinum 12 (22.6%) 29 (54.7%) 12 (22.6%) 53
Cetuximab 4 (16.0%) 9 (36.0%) 12 (48.0%) 25
Treatment technique
IMRT-4X 7 (15.2%) 23 (50.0%) 16 (34.8%) 46
VMAT-6X 15 (27.3%) 30 (54.5%) 10 (18.2%) 55
Sex
Male 16 (20.8%) 37 (51.4%) 22 (27.8%) 75
Female 6 (24.1%) 16 (58.6%) 4 (17.2%) 26
Age (years)
< 67 10 (18.2%) 32 (58.2%) 13 (23.6%) 55
≥ 67 12 (26.1%) 21 (45.7%) 13 (28.3%) 46
BMI (kg/m2)
< 18.5 2 (8.0%) 14 (56.0%) 9 (36.0%) 25
≥ 18.5 20 (26.3%) 39 (51.3%) 17 (22.4%) 76
Diabetes
Yes 3 (23.0%) 7 (53.9%) 3 (23.1%) 13
No 19 (22.0%) 46 (52.3%) 23 (26.1%) 88
Hypertension
Yes 7 (23.0%) 18 (60.0%) 5 (16.7%) 30
No 15 (21.0%) 35 (49.3%) 21 (29.6%) 71
Any comorbidity
(Charlson Comorbidity Index> 1)
Yes 1 (10.0%) 5 (50.0%) 4 (40.0%) 10
No 21 (23.0%) 48 (52.8%) 22 (24.2%) 91
Smoking
Concurrent 7 (17.0%) 20 (48.8%) 14 (34.1%) 41
Ex 7 (19.0%) 21 (56.8%) 9 (24.3%) 37
Never 8 (35.0%) 12 (52.2%) 3 (13.0%) 23
Abbreviations: BMI = body mass index
Table 6 Factor estimates as determined by LRA
Estimate P-value Score assigned
V60Gy (≥ 38 cm
3) 1.8311 < 0.01 2.0
BMI (< 18.5 kg/m2) 0.9547 < 0.01 1.0
Age (≥67 years) 0.8699 < 0.01 1.0
Concurrent chemotherapy
Platinum 1.1227 < 0.01 1.0
Cetuximab 2.2713 < 0.01 2.0
Table 7 Radiation dermatitis scoring system
0 point 1 point 2 points
V60Gy (cm
3) < 38 ≥ 38
BMI (kg/m2) ≥18.5 < 18.5
Age (years) < 67 ≥67
Concurrent chemotherapy None Platinum Cetuximab
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from a clinical trial of concurrent chemoradiotherapy to
treat nasopharyngeal cancer, suggests cropping 2–3 mm
below the body surface [25]. During real-life IMRT, we
do not constrain the skin contour or draw DVHs, but
potential skin issues should be discussed with high-risk
patients. Many anti-cancer agents enhance the sensitivity
to radiotherapy and may increase cellular damage and
hinder tissue repair. Conventional chemotherapeutic agents
and anticancer therapies featuring EGFR inhibitors increase
the risk of severe radiation dermatitis. Giro et al. reported
that a high rate of severe dermatitis was observed during
radiotherapy combined with concurrent chemotherapy,
and recommended treatment interruption if confluent
moist desquamation develops at a total dose < 40 Gy
[26]. Radiation dermatitis profoundly impacts the QOL,
causing pain, infections, and bleeding, and also com-
promises treatment outcomes because of interruption
to radiation schedules [4–6]. Appropriate management
by risk classification is essential.
Generally, patients with Grade 1 radiation dermatitis
are treated nonspecifically via general prevention measures.
Dry desquamation can be treated with hydrophilic





Fig. 3 Representative images of patients with dermatitis of various grades. Skin that received 20 Gy (V20Gy): yellow; V60Gy: orange
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moisturisers, and pruritus and irritation respond to low- to
mid-potency steroids. For patients with Grade 2–3 derma-
titis featuring moist desquamation, treatment should be
directed towards prevention of secondary infection and
dressing the desquamation [27–30]. Treatment of each
dermatitis grade requires a multidisciplinary approach, in-
volving a radiation oncologist, nurse, wound specialist, and
dermatologist.
In our study, BMI, age, and concurrent chemotherapy
were significant predictor as other factors of acute toxic-
ities. Treatment technique, sex, co-existing morbidities,
diabetes, hypertension, smoking were not significant.
Low Nutritional status and older age may delay wound
repair, and concurrent chemotherapy enhances radiosen-
sitizing effect, which increase not only therapeutic ef-
fects but also adverse events. A previous study reported
the predictors of acute radiotherapeutic toxicities in-
clude sex, performance status, and nutritional status,
and TNM stage [8]. Sex and TNM stage reflect RT doses
in this previous study, so dose parameter and nutritional
status are compatible with our study.
To the best of our knowledge, this is the first DVH-based
analysis of how skin structure combined with other factors
predicts the risk for acute dermatitis in HNC patients
undergoing IMRT. During 2D/3D-CRT, the skin dose is
homogeneous and can be estimated, but the dose is not
homogeneous during IMRT, and conversion of isodoses to
structure-level doses is required. No clear dose indications
in terms of risk for severe, acute skin reactions are available.
Our model calculates the probability of severe acute
dermatitis for individual patients. Of all patients, 58.6%
of high-risk, 20.5% of intermediate-risk, and 0% of low-
risk patients developed severe acute dermatitis. Using dose
parameters, and clinical factors including BMI, age, and
concurrent chemotherapy status, we predicted the devel-
opment of acute skin reactions more accurately than that
predicted using dose parameters alone, facilitating the ap-
propriate management of radiation dermatitis.
This scoring system should be evaluated prospectively
or validated on retrospective multicentre cohort prior to
implementation into clinical practice. In addition, our
model should be expanded to include other physical pa-
rameters or genotypic data to improve sensitivity and
specificity. Finally, an objective dermatitis evaluation
method is needed, as CTCAE is subjective. One poten-
tial option is real-time laser Doppler flowmetry, which
quantitatively detects changes in cutaneous microcircu-
lation reflecting radiation-induced skin injury; use of this
method should be investigated in the future [30].
Conclusions
We generated a new risk analysis model including dose-
volume and other parameters, which successfully pre-
dicted the development of acute skin reactions. Thereby
this model could be useful to facilitate the appropriate
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